Showing 1-30 of 560 results for "

C2210000

"
J L Trevaskis et al.
Diabetes, obesity & metabolism, 17(1), 61-73 (2014-09-11)
To test the impact of cholecystokinin (CCK) plus either amylin or a glucagon-like peptide-1 receptor (GLP-1R) agonist on metabolic variables in diet-induced obese (DIO) rodents. A stabilized acetylated version of CCK-8 (Ac-Y*-CCK-8), selective CCK1 receptor (CCK1R) or CCK2 receptor (CCK2R)...
Yinu Wang et al.
Cancer research, 74(17), 4922-4936 (2014-07-19)
Emerging results indicate that cancer stem-like cells contribute to chemoresistance and poor clinical outcomes in many cancers, including ovarian cancer. As epigenetic regulators play a major role in the control of normal stem cell differentiation, epigenetics may offer a useful...
Shenxu Wang et al.
Experimental lung research, 40(8), 404-414 (2014-08-26)
To investigate the effect of cisplatin on the growth and metastasis abilities of lung cancer stem cells (CSCs) via molecular imaging. The expression changes of lung CSCs cell marker in A549-Luc-C8 human non-small-cell lung cancer (NSCLC) cell line with or...
Xinli Huang et al.
Molecular medicine reports, 10(4), 2153-2159 (2014-08-15)
Previous studies revealed that Kanglaite (KLT) exhibits antitumor and immunomodulatory activities. In the present study, we show that KLT treatment stimulated the immune response by increasing the number of T cells and natural killer (NK) cells in the blood of...
Lamiaa A Ahmed et al.
PloS one, 9(10), e108889-e108889 (2014-10-02)
Mitochondrial dysfunction is a crucial mechanism by which cisplatin, a potent chemotherapeutic agent, causes nephrotoxicity where mitochondrial electron transport complexes are shifted mostly toward imbalanced reactive oxygen species versus energy production. In the present study, the protective role of tempol...
Mariana Segovia-Mendoza et al.
BMC cancer, 15, 21-21 (2015-01-28)
Over the past few years, the concurrent use of cisplatin-based chemotherapy and radiation therapy has dramatically improved the local response and increased overall survival in early-stage cervical cancer. However, for the advanced stages of the disease this standard treatment has...
Yoriko Murata et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(7), 933-936 (2013-07-19)
A 67-year-old woman was diagnosed as having advanced gastric cancer(poorly differentiated adenocarcinoma)with multiple liver metastases. She had received combined S-1 plus cisplatin chemotherapy as first-line treatment and weekly paclitaxel chemotherapy as second-line treatment, however, both had eventually proved ineffective. Because...
Toshiaki Yasui et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(12), 2229-2231 (2014-01-08)
The patient was a 50-year-old man diagnosed as having a large type 3 advanced gastric cancer with para-aortic lymph node metastasis and with positive peritoneal cytology. We administered a combined systemic and intraperitoneal chemotherapy involving docetaxel, cisplatin, and S-1 (DCS)....
Maire F Osborn et al.
ACS chemical biology, 9(10), 2404-2411 (2014-07-24)
With the importance of RNA-based regulatory pathways, the potential for targeting noncoding and coding RNAs by small molecule therapeutics is of great interest. Platinum(II) complexes including cisplatin (cis-diamminedichloroplatinum(II)) are widely prescribed anticancer compounds that form stable adducts on nucleic acids....
Yu-Jen Cheng et al.
Oncotarget, 5(22), 11564-11575 (2014-10-27)
Adjuvant chemotherapy is commonly given to surgically treated non-small-cell lung cancer (NSCLC) patients. However, the prerequisite for chemotherapy needs to be scrutinized in order to maximize the benefits to patients. In this study, we observed that NSCLC cells with high...
Yan Wang et al.
Biochemical pharmacology, 90(4), 356-366 (2014-06-15)
Ovarian cancer is commonly treated with anticancer agents; however, many tumors become resistant. Resistance is regulated, in part, by P-glycoprotein, which is encoded by the gene multiple drug resistance 1 (MDR1) and functions as a transmembrane efflux pump for the...
Jian-Jun Xie et al.
Oncotarget, 5(18), 8569-8582 (2014-08-26)
ATF3 was a transcription factor involved in the progression of certain cancers. Here, we sought to explore the expression and biological function of ATF3 in esophageal squamous cell carcinomas (ESCC). The prognostic significance of ATF3 expression was evaluated in 150...
Ivana Sullivan et al.
Cancer letters, 353(2), 160-166 (2014-07-30)
Genetic variants in DNA repair genes may play a role in the effectiveness of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). We analyzed 17 SNPs in eight genes (ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, XPA, XRCC1 and XRCC2) involved in...
Zhongwu Li et al.
Laboratory investigation; a journal of technical methods and pathology, 94(12), 1431-1445 (2014-10-07)
The polycomb complex protein Bmi1 (B lymphoma Mo-MLV insertion region 1 homolog) mediates epigenetic transcriptional silencing by modifying chromatin structure and is critical for stem cell homeostasis and tumorigenesis. Bmi1 is frequently overexpressed in human malignancies and therefore has key...
Dejian Li et al.
Oncology reports, 33(5), 2291-2298 (2015-03-12)
Cancer stem cells (CSCs) have been reported in many tissues. However, CSCs have yet to be identified in a human malignant fibrous histiocytoma (MFH) cell line. Elevated aldehyde dehydrogenase 1 (ALDH1) has been proposed as a stem cell marker for...
Wolfgang Hohenforst-Schmidt et al.
Journal of Cancer, 5(5), 344-350 (2014-04-12)
Inhaled therapy for lung cancer is a local form of treatment. Currently inhaled non-specific cytotoxic agents have been evaluated as a future treatment for local disease control and distant metastasis control. There are few information regarding the influence of local...
Jong-Lyel Roh et al.
Apoptosis : an international journal on programmed cell death, 19(11), 1594-1602 (2014-08-13)
Head and neck cancer (HNC), one of the most common cancers worldwide, frequently involves mutation of the TP53 gene and dysregulation of the p53 pathway. Overexpression of MDM2 or MDM4 inactivates the tumor-suppressive function of p53. Restoration of p53 function...
Hee Jun Cho et al.
International journal of cancer, 135(7), 1553-1563 (2014-03-04)
Rho GDP dissociation inhibitor 2 (RhoGDI2) expression is correlated with tumor growth, metastasis and chemoresistance in gastric cancer. However, the mechanisms by which RhoGDI2 promotes tumor cell survival and metastasis remain unclear. In this study, we clearly demonstrate that RhoGDI2...
Mira Pavkovic et al.
Toxicology, 324, 147-157 (2014-06-01)
Extracellular microRNAs (miRNAs) have emerged as novel biomarkers (BMs) for various pathological states. To evaluate whether urinary miRNAs could serve as biomarkers for drug-induced kidney injury, we performed a nephrotoxicity study in rats with cisplatin (Cp), which is known to...
E2F1-regulated DROSHA promotes miR-630 biosynthesis in cisplatin-exposed cancer cells.
Cao JX, Li SY, An GS, et al.
Biochemical and Biophysical Research Communications, 450(1), 470-475 (2014)
Lin-Hai Yan et al.
American journal of cancer research, 5(1), 321-332 (2015-01-30)
Modulator of multidrug resistance (MDR) gene is a direct transcriptional target of CDX2. However, we still speculate whether CDX2 affects MDR through other ways. In this study, a cisplatin-resistant (SGC7901/DDP) and a 5-fluoro-2, 4(1h,3h)pyrimidinedione-resistant (BGC823/5-FU) gastric cancer cell line with...
Sachiko Ogasawara et al.
Journal of gastroenterology and hepatology, 30(2), 413-420 (2014-08-05)
Human combined hepatocellular-cholangiocarcinoma (CHC) expresses several hepatic stem/progenitor cell (HSPC) markers, suggesting this neoplasm originates from HSPCs. We examined the significance of HSPC marker in CHC using a human CHC cell line. We used a human CHC cell line (KMCH-1)...
Keng Po Lai et al.
International journal of cancer, 135(8), 1790-1799 (2014-03-04)
Zinc finger protein X-linked (ZFX) is a zinc finger protein of Zfy family, which is highly conserved in vertebrates. This transcriptional regulator is not only highly expressed in embryonic stem cells (ESC) and hematopoietic stem cells, but is also upregulated...
Xiaoyi Sun et al.
Die Pharmazie, 69(4), 281-286 (2014-05-06)
The polycation transfection agent, polyethylenimine (PEI) was introduced into cisplatin (CDDP)-encapsulated liposomes by modification with amphiphilic PEI-cholesterol (PEI-Chol) to evaluate its potential application in chemotherapeutic drug delivery. Compared with unmodified neutral liposomes (CDDP-NL), the remarkable features of PEI-modified cationic liposomes...
Erika Ortolan et al.
Oncotarget, 5(15), 6191-6205 (2014-07-16)
Malignant mesothelioma is a deadly tumor whose diagnosis and treatment remain very challenging. There is an urgent need to advance our understanding of mesothelioma biology and to identify new molecular markers for improving management of patients. CD157 is a membrane...
Keiji Kajihara et al.
Gan to kagaku ryoho. Cancer & chemotherapy, 40(12), 2310-2312 (2014-01-08)
We report a case of lethal interstitial pneumonia that occurred after neoadjuvant chemotherapy for advanced gastric cancer. A 76-year-old man with no history of interstitial pneumonia received 2 courses of S-1 (100 mg/body) following 1 course of S-1 plus cisplatin(...
Hannah Kenward et al.
Experimental brain research, 232(8), 2685-2697 (2014-05-06)
Cisplatin is a highly emetogenic cancer chemotherapy agent, which is often used to induce nausea and emesis in animal models. The cytotoxic properties of cisplatin also cause adverse events that negatively impact on animal welfare preventing repeated administration of cisplatin....
Sung-Hyun Jung et al.
Molecules and cells, 37(3), 234-240 (2014-03-20)
Cisplatin is one of the most potent chemotherapy agents. However, its use is limited due to its toxicity in normal tissues, including the kidney and ear. In particular, nephrotoxicity induced by cisplatin is closely associated with oxidative stress and inflammation....
B Zhang et al.
European review for medical and pharmacological sciences, 18(11), 1595-1601 (2014-06-20)
In a previous analysis using a lung cancer cell lines model, we have found that therapies directed against sCLU and its downstream signaling targets pAkt and pERK1/2 may have the potential to enhance the efficacy of cisplatin (DDP)-based chemotherapy in...
Scott R Burks et al.
Stem cells (Dayton, Ohio), 33(4), 1241-1253 (2015-02-03)
Animal studies have shown that mesenchymal stromal cell (MSC) infusions improve acute kidney injury (AKI) outcomes when administered early after ischemic/reperfusion injury or within 24 hours after cisplatin administration. These findings have spurred several human clinical trials to prevent AKI....